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Background: Diagnosing tuberculous pleural effusion (pTB) is often difficult because
the culturing of tubercle bacilli results in a negative test in the majority of cases.
Serological tests for the detection of antibodies to tuberculous glycolipid (TBGL) and
lipoarabinomannan (LAM) have been introduced for the diagnosis of pulmonary
tuberculosis. We examined the levels of these antibodies, adenosine deaminase (ADA)
and interferon-g (IFN-g) in the pleural effusion and compared their diagnostic values in
pTB.
Methods: We studied 65 patients with pleural effusion. Of those, 19 patients were
diagnosed as having pTB according to our broad case definition. The etiologies in the
other 46 patients were malignant effusion, transdative effusion and miscellaneous
diseases. Determiner TBGL antibodys (D-TBGL-Ab) and MycoDots were used for the
detection of anti-LAM and anti-TBGL antibodies, respectively, in the pleural
effusion.
Results: The sensitivity of ADA was 78.9% (15/19) and the specificity 97.8%
(45/46). The sensitivity of IFN-g was 84.2% (16/19) and the specificity 93.5%
(43/46). The sensitivities of D-TBGL-Ab and MycoDots were both 52.6%
(10/19) and their specificities were 95.7% (44/46) and 97.8% (45/46), res-
pectively. When DTBGL-Ab (cutoff point: 2.0 U/ml) and ADA activity (cutoff point:
57 IU/l) were combined, the sensitivity was 94.7% (18/19) and the specificity 93.5%
(43/46).
Conclusions: In the diagnosis of pTB, D-TBGL-Ab and MycoDots each have low
sensitivity but high specificity. When D-TBGL-Ab is used in combination with ADA, theElsevier Ltd. All rights reserved.
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combination are useful in the diagnosis of pTB.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Many diseases cause pleural diseases,1,2 and tuber-
culosis (TB) remains the most common cause of
pleural effusion in many countries.3 The diagnosis
of tuberculous pleural effusion (pTB) is made by
demonstrating the existence of tubercle bacilli in
the sputum, the pleural fluid, or the pleural biopsy
specimen, or by demonstrating the existence of
granulomas in the pleura.4,5 In many cases, how-
ever, it is difficult to diagnose pTB. There are many
biological markers which have been proposed to
increase the diagnostic sensitivity to pTB.6 So far,
adenosine deaminase (ADA) activity has been
considered the most useful marker, although it is
not elevated in all pTB patients. Recent studies
have shown that interferon-g (IFN-g) is elevated in
pTB, and it is thought to be a more sensitive
diagnostic tool than ADA.4,7,8 However, the eleva-
tion of either ADA or IFN-g is not a specific reaction
to TB.6
Recently, new serological tests for the detection
of antibodies against tuberculous glycolipid (TBGL),
including trehalose-6,60-dimycolate (TDM) and li-
poarabinomannan (LAM), a glycolipid common in
mycobacteria, have been developed for the diag-
nosis of pulmonary TB.9,10 The positive and nega-
tive predictive value of serological diagnostic
testing using glycolipids, however, may be influ-
enced greatly by the prevalence of the disease in
each country.11 Because one of the mechanisms of
pTB is a hypersensitive response to mycobacterial
protein, we thought that measuring the level of
antibodies against the glycolipid of TB in the
pleural effusion might be a more useful diagnostic
approach than serological examination.3 In this
study, we examined the level of antibodies against
TBGL in the pleural effusion. We also examined the
levels of ADA activity and IFN-g, and compared the
diagnostic value of these tests.Methods
Patients
We examined 65 patients with pleural effusion who
were referred to Hirosaki University Hospital. They
were 49 men and 16 women, and their mean agewas 60 years, ranging from 20 to 81 years. All
patients had undergone a clinical work-up for
pleural effusion, including pleurocentesis, and the
pleural effusion samples were kept at 80 1C.
The diagnosis of pTB was made when acid-fast
bacilli were detected in the pleural effusion or in
other biological materials by microscopy, when
Mycobacterium tuberculosis was detected upon
culturing, or when granulomatous inflammatory
change with necrosis was found in the pleural
biopsy specimen. The patients who responded to
3- or 6-month empirical anti-TB therapy and did not
have any other disease were also considered to
have pTB. According to these criteria, 19 patients
were diagnosed as having pTB (pTB group) and the
other 46 as not having pTB (non-pTB group). The
non-pTB group consisted of 33 patients with
malignant pleural effusion and lung or other cancer,
4 with parapneumonic effusion, 2 with collagen
disease, 6 with congestive heart or renal failure,
and 1 with postoperative pleural effusion after
coronary-artery bypass grafting.Measurement of ADA activity and IFN-c level
in the pleural effusion
The ADA activity and IFN-g level were determined
for all samples. The ADA activity was measured by
enzyme assay using the UV-RATE method (MIZUHO
MEDY. Co., Ltd., Saga, Japan). The IFN-g level was
measured by ELISA (R&D Systems, Inc., Minneapolis,
MN, USA).Detection of antibodies against TDM and
other minor glycolipids of the cell wall of
Mycobacterium tuberculosis in the pleural
effusion
Determiner TBGL antibodys (D-TBGL-Ab) (Kyowa-
Medex Co., Ltd., Tokyo, Japan) detects the anti-
body against TDM, trehalose 6-mycolate, 2,3-
diacyltrehalose, phenolic, TBGL, etc., all of which
derive from the glycolipids of TB. TDM is a
characteristic cord factor of the mycobacterial
membrane, including TB. D-TBGL-Ab is a quantita-
tive analysis kit for rapid serodiagnosis. We used
400 ml of sample diluent, and 10 ml of pleural fluid
instead of serum.
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pleural effusion
MycoDots (Mossman Associates Inc., Blackstone,
MA, USA) detects the antibody against LAM. If the
anti-mycobacterial antibody is detected in the
specimen, colloidal gold particles will specifically
aggregate to the antigen location on the test comb
to give a colored dot indicative of a positive
reaction. We used 100 ml of the sample diluent,
and 100 ml of pleural fluid instead of serum.
Statistical analysis
All data are expressed as means (and ranges),
unless otherwise stated. The data were compared
using the Mann-Whitney and Chi-square tests
between the pTB group and the non-pTB group.
We determined all cutoff points by likelihood ratio
(LR) analysis, except in the case of MycoDots.
Receiver operating characteristic (ROC) curve
analysis was used to compare the usefulness of
each marker.Results
ADA activity and IFN-c level
The mean ADA activity was 68.8 IU/l (range:
12.9–125.9 IU/l) in the pTB group and 16.0 IU/l
(range: 3.4–88.0 IU/l) in the non-pTB group
(Po0:0001) (Fig. 1A). The mean IFN-g was
1453.9 pg/ml (range: 0–3832.7 pg/ml) in the TB
group and 51.7 pg/ml (range 0–626.0 pg/ml) in the
non-TB group (Po0:0001) (Fig. 1B).
Determiner TBGL antibodys and antibody
against LAM
The mean D-TBGL-Ab was 4.97U/ml (range:
0–32.36 U/ml) in the pTB group and 0.64 U/ml
(range: 0–2.97 U/ml) in the non-pTB group
(P ¼ 0:0004) (Fig. 1C). In terms of the MycoDots
test, there were 10 positive samples in the pTB
group, while there were 45 negative samples and 1
positive sample in the non-pTB group (Po0:0001)
(Fig. 1D).
Sensitivity, specificity and the ROC curve
The sensitivity, specificity and positive and nega-
tive predictive value determined at each of the
three levels are shown in Table 1 for all tests used
in this study. The best cutoff points were deter-mined by LR. When the ADA cutoff point was set at
57.0 U/ml, the sensitivity was 78.9% and the
specificity 97.8%. When the IFN-g cutoff point was
set at 248 pg/ml, the sensitivity was 84.2% and the
specificity 93.5%. When the D-TBGL-Ab cutoff point
was set at 2.0 U/ml, the sensitivity was 52.6% and
the specificity 95.7%. As for MycoDots, the
diagnostic sensitivity for pTB was 52.6% and the
specificity 97.8%.
The ROC curves for the ADA activity, IFN-g level
and D-TBGL-Ab level are shown in Fig. 2. ROC curve
analysis showed that ADA activity was the best
indicator among the three markers. To obtain a
better diagnostic value, we combined the results of
the tests two by two and compared the resulting
diagnostic precisions (Table 1). It was found that
when D-TBGL-Ab (cutoff point: 2.0 U/ml) and ADA
activity (cutoff point: 57 IU/l) were combined, the
sensitivity was 94.7% (18/19) and the specificity
93.5% (43/46). This combination was the most
sensitive and specific for the diagnosis of pTB.Discussion
Recently, serological diagnostic kits for TB diag-
nosis, such as D-TBGL-Ab and MycoDots, have
became available. The reported sensitivity and
specificity of D-TBGL-Ab are 66–90% and
95–99%,9,10,12–16 respectively. The sensitivity and
specificity of MycoDots are reported to be 41–90%
and 84–100%,11,17–23 respectively. The range of
sensitivity in both of these tests is wide because
the diagnostic value of these tests is influenced
greatly by the prevalence of TB in the population
being studied. Actually, populations which have
undergone prior bacillus Calmette-Guerin (BCG)
vaccination tend to show positive responses to the
serologic test for TB,11 which in turn results in
decreased specificity. Thus, these serological tests
for TB might not be useful.
In many areas of the world, TB still remains the
most common cause of pleural effusion. However,
the culturing of sampled effusion yields negative
results in the majority of patients with pTB. In our
study, the positive reactions of MycoDots were
judged visually, and 10 out of 19 samples were
positive in this study. D-TBGL-Ab and MycoDots
were found to have high specificities, but the
sensitivities of these tests were lower than we
expected. Low levels of anti-mycobacterial anti-
body in the pleural effusion have been reported
previously.24 The pleural fluid in patients with
pleural TB dose not usually contain a large antigen
load because of the small number of organisms. And
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Figure 1 Concentrations of adenosine deaminase (ADA) (A), interferon-g (IFN-g) (B), and Determiner TBGL antibodys
(D-TBGL-Ab) (C) in the pleural effusion.
Table 1 Sensitivity and specificity of three different levels of ADA, IFN-g, Determinar TBGL antibody (D-TBGL-Ab)
and MycoDots for diagnosing pTB.
Sensitivity
(%)
Specificity
(%)
Positive predictive
value (%)
Negative
predictive value
(%)
Likelihood
ratio
ADA ActivityX50 IU/l 78.9 (15/19) 95.7 (44/46) 88.2 91.7 18.2
ADA activityX57 IU/l 78.9 (15/19) 97.8 (45/46) 93.8 91.8 36.3
ADA activityX58 IU/l 73.7 (14/19) 97.8 (45/46) 93.3 90.0 33.9
IFN-g levelsX195 pg/ml 84.2 (16/19) 91.3 (42/46) 80.0 93.3 9.7
IFN-g levelsX248 pg/ml 84.2 (16/19) 93.5 (43/46) 84.2 93.5 12.9
IFN-g levelsX260 pg/ml 78.9 (15/19) 93.5 (43/46) 83.3 91.5 12.1
D-TBGL-AbX1.9 U/ml 52.6 (10/19) 93.5 (43/46) 76.9 82.6 8.1
D-TBGL-AbX2.0 U/ml 52.6 (10/19) 95.7 (44/46) 83.3 83.0 12.1
D-TBGL-AbX2.4 U/ml 47.4 (9/19) 95.7 (44/46) 81.8 81.4 10.8
MycoDotsXpositive 52.6 (10/19) 97.8 (45/46) 90.9 83.3 24.2
T. Morimoto et al.1778this can explain the low sensitivity of these
serological tests.
There have been many reports on the usefulness
of ADA activity and IFN-g level in the diagnosis of
pTB. These reports have shown that the range ofsensitivity and specificity of ADA activity are
69–100% and 72–100%, respectively,5,6,25,26
whereas the sensitivity and specificity of the IFN-g
level are 80–100% and 90–100%, respectively.4,6–8
Our data were consistent with these reports. We
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Figure 2 Receiver operating characteristic (ROC) curve
for the diagnosis of tuberculous pleural effusion and area
under the curves (AUC). ADA ¼ adenosine deaminase;
IFN-g ¼ interferon-g; D-TBGL-Ab ¼ Determiner TBGL
antibodys.
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area under the ROC curve among these tests, and
this comparison showed that ADA activity was the
most useful diagnostic tool.
A positive correlation between ADA activity and
the IFN-g level in the pleural effusion of our present
subjects has been observed. ADA is found in
monocytes and macrophages, while IFN-g is pro-
duced by activated CD4+ T lymphocytes.3,8 These
cells constitute the chain of response to mycobac-
terial infection.6 However, not only specific anti-
gens, such as tubercle bacilli but also non-specific
antigens stimulate CD4+ T lymphocytes and elevate
the IFN-g level. Therefore, the elevation of ADA
activity and IFN-g in the pleural effusion is not
specific to TB. In fact, we observed elevated ADA
activity in a patient with thymoma.
The D-TBGL-Ab test and MycoDots test were
found to be specific to TB cases, although a few
positive results were obtained in non-pTB cases.
Therefore, we examined the diagnostic value of the
combination between each of these antibody tests
and ADA activity or the INF-g level. When D-TBGL-Ab
(cutoff point: 2.0 U/ml) and the ADA activity
(cutoff point: 57U/ml) were combined, the sensi-
tivity was 94.7%, and the specificity 93.5%, the
positive predictive value was 85.7%, and the
negative predictive value 97.7%. This combination
was the most effective in diagnosing pTB in our
study. However, when studying large populations
where TB is endemic, we should consider theexpense involved in administering these tests.
Measurement of the ADA activity in pleural fluid is
the most cost-effective method. When the diag-
nosis of pTB is uncertain, the D-TBGL-Ab test or the
MycoDots test using pleural effusion instead of
serum is recommended.
In conclusion, the measurement of anti-LAM
antibodies and anti-TBGL antibodies in the pleural
effusion is useful for the diagnosis of pTB. In
addition to measuring the ADA activity in the
pleural effusion, measuring the anti-TBGL antibody
levels in the pleural effusion seems to be an
excellent diagnostic method for the diagnosis
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